December 2021 OMass Therapeutics's founder, Carol Robinson, has been awarded the prestigious Louis-Jeantet Franklin Medal in Chemistry from The Franklin Institute yesterday for contributions to the field of mass

November 2021 "Nov. 15, 2021 LONDON – There’s not yet proof of the pudding, but Omass Therapeutics Ltd

Chemistry, former president of the Royal Society of Chemistry and Founder of (and ongoing consultant to) OMass Therapeutics, which is based at Oxford Science Park, has been awarded the 2022 Louis-Jeantet Prize for

Juan Jose Fung , principal scientist at GPCR Therapeutics followed by Dr. Nicola Smith and Dr. Pina Cardarelli , CSO of GPCR Therapeutics. Are you going to be our next podcast guest? Odorant G protein-coupled receptors as potential therapeutic targets for adult diffuse gliomas: a systematic G-protein-coupled receptors as therapeutic targets for glioblastoma. Deane Joins Exscientia as Chief Scientist of Biologics AI Oxford Professor of Chemistry and Founder of OMass

Pina Cardarelli from GPCR Therapeutics as well as Dr. Marta Filizola. GPCR neuromodulation Cholesterol-dependent endocytosis of GPCRs: implications in pathophysiology and therapeutics Molecular Mechanisms and Therapeutic Prospects Luminal Chemosensory Cells in the Small Intestine Melanopsin OB-004 is a GPCR targeted protein analog of CCL2 that targets the CCR2 receptor OMass Therapeutics's Keystone Symposia in-person meeting- GPCRs: An Odyssey from Structure, Signaling, and Regulation to Therapeutics

development of optogenetics Obesity and Gαs Variants Atypical opioid receptors: unconventional biology and therapeutic Opioid Actions Gαs–Protein Kinase A (PKA) Pathway Signalopathies: The Emerging Genetic Landscape and Therapeutic Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics Keystone Symposia in-person meeting- GPCRs: An Odyssey from Structure, Signaling, and Regulation to Therapeutics GPCR-effector protein complexes Kappa Opioid Receptors Revealed: Disentangling the Pharmacology to Open Up New Therapeutic